New human clinical study puts botanicals into the GLP-1 spotlight
The research has generated significant interest from firms in food & supplements as consumers seek natural alternatives to GLP-1 drugs.
The research has generated significant interest from firms in food & supplements as consumers seek natural alternatives to GLP-1 drugs.
Lasso CEO Mike Messersmith: “When you start an email [to an investor] with, ‘Hey, I’m Mike from a plant-based meat company in Boston,’ it’s like, ‘delete.’”